{"id":751840,"date":"2023-04-27T02:03:01","date_gmt":"2023-04-27T06:03:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-expands-contrast-media-portfolio-with-launch-of-mri-agent-pixxoscan-gadobutrol\/"},"modified":"2023-04-27T02:03:01","modified_gmt":"2023-04-27T06:03:01","slug":"ge-healthcare-expands-contrast-media-portfolio-with-launch-of-mri-agent-pixxoscan-gadobutrol","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-expands-contrast-media-portfolio-with-launch-of-mri-agent-pixxoscan-gadobutrol\/","title":{"rendered":"GE HealthCare Expands Contrast Media Portfolio with Launch of MRI Agent Pixxoscan (gadobutrol)"},"content":{"rendered":"<p>        <!--.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>GE HealthCare Expands Contrast Media Portfolio with Launch of MRI Agent Pixxoscan (gadobutrol)<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nThe launch of Pixxoscan expands GE HealthCare\u2019s portfolio of Magnetic Resonance Imaging (MRI) contrast agents, now offering two leading macrocyclic molecules to customers &#8211; Clariscan (gadoteric acid) and Pixxoscan (gadobutrol)<\/p>\n<\/li>\n<li>\nPixxoscan has the same active substance (gadobutrol) and the same qualitative and quantitative composition as the reference product, Gadovist\u00ae<\/p>\n<\/li>\n<li>\nThe availability of Pixxoscan will give radiology departments greater access to agents supporting a broad range of MRI procedures, helping them in personalizing care for patients.<\/p>\n<\/li>\n<\/ul>\n<p>CHALFONT ST GILES, England&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nGE HealthCare has today announced the launch of Pixxoscan (gadobutrol), its macrocyclic, non-ionic Magnetic Resonance Imaging (MRI) gadolinium-based contrast agent (GBCA). Pixxoscan has been reviewed using a regulatory decentralized procedure (DCP) with marketing authorization already in place in Austria and pending approval, will be introduced to a number of European countries in 2023.<\/p>\n<p id=\"news-body-cta\">This press release features multimedia. View the full release here: <a href=\"https:\/\/www.businesswire.com\/news\/home\/20230426005641\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230426005641\/en\/<\/a><\/p>\n<div id=\"bwbodyimg\" style=\"width: 480px;float:left;padding-left:0px;padding-right:20px;padding-top:0px;padding-bottom:0px\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230426005641\/en\/1775265\/4\/2023_Pixxoscan_pressrelease_-_image_%2872dpi_Max_1254x836pix%29_4.jpg\" alt=\"Enhanced Magnetic Resonance (MR) procedure with cardiac scan images (Photo: Business Wire)\" \/><\/p>\n<p style=\"font-size:85%\">Enhanced Magnetic Resonance (MR) procedure with cardiac scan images (Photo: Business Wire)<\/p>\n<\/div>\n<p>\nIt has been reviewed as having the same qualitative and quantitative composition in active substance and excipients, and the same pharmaceutical form, as the reference product, Gadovist.<\/p>\n<p>\nPixxoscan facilitates visualization of abnormal structures or lesions and helps in the differentiation between healthy and pathological tissue. In line with the reference product, Gadovist, Pixxoscan (gadobutrol) is indicated for use in adults, adolescents, and children of all ages (including term neonates) for contrast enhancement in cranial and spinal MRI and magnetic resonance angiography. It is also indicated for whole body imaging, including liver and kidneys in patients with high suspicion or evidence of having focal lesions to classify them as benign or malignant.<\/p>\n<p>\nGadobutrol has a high relaxivity which helps enhance detection, delineation and characterization in MRI across its range of indications. It is also formulated at twice the concentration of gadolinium ions, reducing injection volume by half compared to other GBCAs, providing a tighter bolus. Its cage-like macrocyclic chelate, which encloses the gadolinium, provides high kinetic stability.<\/p>\n<p>\nPixxoscan adds to GE HealthCare\u2019s MRI contrast media portfolio which includes macrocyclic Clariscan (gadoteric acid) as well as Rapiscan, used in stress cardiac MR to aid diagnosis of coronary artery disease and offering an alternative for patients who cannot exercise. The availability of Pixxoscan will give radiology departments greater access to agents supporting a broad range of MRI procedures, helping them in personalizing care for patients.<\/p>\n<p>\nDr Gianluca Pontone, Director of Perioperative Cardiology and Cardiovascular Imaging Department, Monzino Cardiology Center, Milan, Italy, said: \u201cGE HealthCare continues to expand its range of products and Pixxoscan sitting alongside cardiac stress agent, Rapiscan, is welcome news. This gives me, as a cardiologist, the products I need to aid in making timely diagnoses for patients with suspected coronary artery disease.\u201d<\/p>\n<p>\nMark Hibberd, Chief Medical Officer, GE HealthCare Pharmaceutical Diagnostics, said: \u201cThis extension to our portfolio means, we will be able to offer two leading macrocyclic molecules \u2013 Clariscan (gadoteric acid) and Pixxoscan (gadobutrol) &#8211; to our customers in a number of European countries, offering radiology departments even more choice to suit their diagnostic needs. We continue to innovate and invest in our contrast media portfolio to deliver for healthcare professionals and patients and to meet future demand.\u201d<\/p>\n<p>\nPixxoscan (gadobutrol) offers a wide range of packaging encompassing glass vials, ready-assembled plastic prefilled syringes and larger volume +PLUSPAK polypropylene bottles. GE HealthCare\u2019s +PLUSPAK plastic packaging, using flip-top lids, helps eliminate risk of, and downtime from, broken glass and ring-pull injuries. +PLUSPAK also provides more choice for customers and helps them reduce their costs and environmental impact.<\/p>\n<p>\nAs with all GE HealthCare contrast agents, Pixxoscan will be produced in compliance with current Good Manufacturing Practices (cGMP) &#8211; with rigorous testing at our primary and secondary manufacturing sites in Norway to ensure high quality. Once approved, it will then be labelled and packed for onward shipping via our standard distribution network to local markets.<\/p>\n<p>\nGE HealthCare\u2019s Pharmaceutical Diagnostics unit is a global leader in imaging agents used to support around 100 million procedures per year globally, equivalent to three patient procedures every second. For more than 40 years, GE HealthCare imaging agents have been routinely used across MRI, X-ray\/CT and ultrasound to enhance clinical images and support diagnosis.<\/p>\n<p><b>About GE HealthCare Technologies Inc.<br \/>\n<br \/><\/b>GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 100 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient\u2019s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are an $18.3 billion business with 50,000 employees working to create a world where healthcare has no limits.<\/p>\n<p>\nFollow us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FGEHealthCare%2F&amp;esheet=53388220&amp;newsitemid=20230426005641&amp;lan=en-US&amp;anchor=Facebook&amp;index=1&amp;md5=34562b6cd34db6573f76546fb5f6cc19\">Facebook<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fgehealthcare%2Fmycompany%2F&amp;esheet=53388220&amp;newsitemid=20230426005641&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=2&amp;md5=97844e33557a3c3b7dffc6dabfcce4d4\">LinkedIn<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FGEHealthcare&amp;esheet=53388220&amp;newsitemid=20230426005641&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=491b76b913aa5edafaffb9b9d95723d5\">Twitter<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fgehealthcare%2F&amp;esheet=53388220&amp;newsitemid=20230426005641&amp;lan=en-US&amp;anchor=Instagram&amp;index=4&amp;md5=3eb5847702b59c90af8e617995e7531c\">Instagram<\/a>, and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gehealthcare.com%2Finsights%3FshowPopup%3Dfalse&amp;esheet=53388220&amp;newsitemid=20230426005641&amp;lan=en-US&amp;anchor=Insights&amp;index=5&amp;md5=747a2ba7e6875d918f66537d642bbcd8\">Insights<\/a> for the latest news, or visit our website <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gehealthcare.com%2F&amp;esheet=53388220&amp;newsitemid=20230426005641&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.gehealthcare.com%2F&amp;index=6&amp;md5=6460fdcbadf2306a7ee370821f50b3df\">https:\/\/www.gehealthcare.com\/<\/a> for more information.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230426005641r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20230426005641\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230426005641\/en\/<\/a><\/span><\/p>\n<p><b>GE HealthCare Media Contact:<br \/>\n<\/b><br \/>Debbie Leven<br \/>\n<br \/>M +44 778 545 6999<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:Debbie.Leven@ge.com\">Debbie.Leven@ge.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United Kingdom Europe<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Surgery Medical Devices Hospitals Cardiology Biotechnology Health Pharmaceutical General Health Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230426005641\/en\/1775263\/3\/GE-HLTHCR_Standard_RGB-CompPrpl.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Photo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230426005641\/en\/1775265\/3\/2023_Pixxoscan_pressrelease_-_image_%2872dpi_Max_1254x836pix%29_4.jpg\" alt=\"Photo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\">Enhanced Magnetic Resonance (MR) procedure with cardiac scan images (Photo: Business Wire)<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>GE HealthCare Expands Contrast Media Portfolio with Launch of MRI Agent Pixxoscan (gadobutrol) The launch of Pixxoscan expands GE HealthCare\u2019s portfolio of Magnetic Resonance Imaging (MRI) contrast agents, now offering two leading macrocyclic molecules to customers &#8211; Clariscan (gadoteric acid) and Pixxoscan (gadobutrol) Pixxoscan has the same active substance (gadobutrol) and the same qualitative and quantitative composition as the reference product, Gadovist\u00ae The availability of Pixxoscan will give radiology departments greater access to agents supporting a broad range of MRI procedures, helping them in personalizing care for patients. CHALFONT ST GILES, England&#8211;(BUSINESS WIRE)&#8211; GE HealthCare has today announced the launch of Pixxoscan (gadobutrol), its macrocyclic, non-ionic Magnetic Resonance Imaging (MRI) gadolinium-based contrast agent (GBCA). Pixxoscan has been reviewed using a &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-expands-contrast-media-portfolio-with-launch-of-mri-agent-pixxoscan-gadobutrol\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;GE HealthCare Expands Contrast Media Portfolio with Launch of MRI Agent Pixxoscan (gadobutrol)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-751840","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GE HealthCare Expands Contrast Media Portfolio with Launch of MRI Agent Pixxoscan (gadobutrol) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-expands-contrast-media-portfolio-with-launch-of-mri-agent-pixxoscan-gadobutrol\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GE HealthCare Expands Contrast Media Portfolio with Launch of MRI Agent Pixxoscan (gadobutrol) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"GE HealthCare Expands Contrast Media Portfolio with Launch of MRI Agent Pixxoscan (gadobutrol) The launch of Pixxoscan expands GE HealthCare\u2019s portfolio of Magnetic Resonance Imaging (MRI) contrast agents, now offering two leading macrocyclic molecules to customers &#8211; Clariscan (gadoteric acid) and Pixxoscan (gadobutrol) Pixxoscan has the same active substance (gadobutrol) and the same qualitative and quantitative composition as the reference product, Gadovist\u00ae The availability of Pixxoscan will give radiology departments greater access to agents supporting a broad range of MRI procedures, helping them in personalizing care for patients. CHALFONT ST GILES, England&#8211;(BUSINESS WIRE)&#8211; GE HealthCare has today announced the launch of Pixxoscan (gadobutrol), its macrocyclic, non-ionic Magnetic Resonance Imaging (MRI) gadolinium-based contrast agent (GBCA). Pixxoscan has been reviewed using a &hellip; Continue reading &quot;GE HealthCare Expands Contrast Media Portfolio with Launch of MRI Agent Pixxoscan (gadobutrol)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-expands-contrast-media-portfolio-with-launch-of-mri-agent-pixxoscan-gadobutrol\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-27T06:03:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230426005641\/en\/1775265\/4\/2023_Pixxoscan_pressrelease_-_image_%2872dpi_Max_1254x836pix%29_4.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ge-healthcare-expands-contrast-media-portfolio-with-launch-of-mri-agent-pixxoscan-gadobutrol\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ge-healthcare-expands-contrast-media-portfolio-with-launch-of-mri-agent-pixxoscan-gadobutrol\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"GE HealthCare Expands Contrast Media Portfolio with Launch of MRI Agent Pixxoscan (gadobutrol)\",\"datePublished\":\"2023-04-27T06:03:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ge-healthcare-expands-contrast-media-portfolio-with-launch-of-mri-agent-pixxoscan-gadobutrol\\\/\"},\"wordCount\":916,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ge-healthcare-expands-contrast-media-portfolio-with-launch-of-mri-agent-pixxoscan-gadobutrol\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230426005641\\\/en\\\/1775265\\\/4\\\/2023_Pixxoscan_pressrelease_-_image_%2872dpi_Max_1254x836pix%29_4.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ge-healthcare-expands-contrast-media-portfolio-with-launch-of-mri-agent-pixxoscan-gadobutrol\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ge-healthcare-expands-contrast-media-portfolio-with-launch-of-mri-agent-pixxoscan-gadobutrol\\\/\",\"name\":\"GE HealthCare Expands Contrast Media Portfolio with Launch of MRI Agent Pixxoscan (gadobutrol) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ge-healthcare-expands-contrast-media-portfolio-with-launch-of-mri-agent-pixxoscan-gadobutrol\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ge-healthcare-expands-contrast-media-portfolio-with-launch-of-mri-agent-pixxoscan-gadobutrol\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230426005641\\\/en\\\/1775265\\\/4\\\/2023_Pixxoscan_pressrelease_-_image_%2872dpi_Max_1254x836pix%29_4.jpg\",\"datePublished\":\"2023-04-27T06:03:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ge-healthcare-expands-contrast-media-portfolio-with-launch-of-mri-agent-pixxoscan-gadobutrol\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ge-healthcare-expands-contrast-media-portfolio-with-launch-of-mri-agent-pixxoscan-gadobutrol\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ge-healthcare-expands-contrast-media-portfolio-with-launch-of-mri-agent-pixxoscan-gadobutrol\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230426005641\\\/en\\\/1775265\\\/4\\\/2023_Pixxoscan_pressrelease_-_image_%2872dpi_Max_1254x836pix%29_4.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230426005641\\\/en\\\/1775265\\\/4\\\/2023_Pixxoscan_pressrelease_-_image_%2872dpi_Max_1254x836pix%29_4.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ge-healthcare-expands-contrast-media-portfolio-with-launch-of-mri-agent-pixxoscan-gadobutrol\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GE HealthCare Expands Contrast Media Portfolio with Launch of MRI Agent Pixxoscan (gadobutrol)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GE HealthCare Expands Contrast Media Portfolio with Launch of MRI Agent Pixxoscan (gadobutrol) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-expands-contrast-media-portfolio-with-launch-of-mri-agent-pixxoscan-gadobutrol\/","og_locale":"en_US","og_type":"article","og_title":"GE HealthCare Expands Contrast Media Portfolio with Launch of MRI Agent Pixxoscan (gadobutrol) - Market Newsdesk","og_description":"GE HealthCare Expands Contrast Media Portfolio with Launch of MRI Agent Pixxoscan (gadobutrol) The launch of Pixxoscan expands GE HealthCare\u2019s portfolio of Magnetic Resonance Imaging (MRI) contrast agents, now offering two leading macrocyclic molecules to customers &#8211; Clariscan (gadoteric acid) and Pixxoscan (gadobutrol) Pixxoscan has the same active substance (gadobutrol) and the same qualitative and quantitative composition as the reference product, Gadovist\u00ae The availability of Pixxoscan will give radiology departments greater access to agents supporting a broad range of MRI procedures, helping them in personalizing care for patients. CHALFONT ST GILES, England&#8211;(BUSINESS WIRE)&#8211; GE HealthCare has today announced the launch of Pixxoscan (gadobutrol), its macrocyclic, non-ionic Magnetic Resonance Imaging (MRI) gadolinium-based contrast agent (GBCA). Pixxoscan has been reviewed using a &hellip; Continue reading \"GE HealthCare Expands Contrast Media Portfolio with Launch of MRI Agent Pixxoscan (gadobutrol)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-expands-contrast-media-portfolio-with-launch-of-mri-agent-pixxoscan-gadobutrol\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-27T06:03:01+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230426005641\/en\/1775265\/4\/2023_Pixxoscan_pressrelease_-_image_%2872dpi_Max_1254x836pix%29_4.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-expands-contrast-media-portfolio-with-launch-of-mri-agent-pixxoscan-gadobutrol\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-expands-contrast-media-portfolio-with-launch-of-mri-agent-pixxoscan-gadobutrol\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"GE HealthCare Expands Contrast Media Portfolio with Launch of MRI Agent Pixxoscan (gadobutrol)","datePublished":"2023-04-27T06:03:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-expands-contrast-media-portfolio-with-launch-of-mri-agent-pixxoscan-gadobutrol\/"},"wordCount":916,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-expands-contrast-media-portfolio-with-launch-of-mri-agent-pixxoscan-gadobutrol\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230426005641\/en\/1775265\/4\/2023_Pixxoscan_pressrelease_-_image_%2872dpi_Max_1254x836pix%29_4.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-expands-contrast-media-portfolio-with-launch-of-mri-agent-pixxoscan-gadobutrol\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-expands-contrast-media-portfolio-with-launch-of-mri-agent-pixxoscan-gadobutrol\/","name":"GE HealthCare Expands Contrast Media Portfolio with Launch of MRI Agent Pixxoscan (gadobutrol) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-expands-contrast-media-portfolio-with-launch-of-mri-agent-pixxoscan-gadobutrol\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-expands-contrast-media-portfolio-with-launch-of-mri-agent-pixxoscan-gadobutrol\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230426005641\/en\/1775265\/4\/2023_Pixxoscan_pressrelease_-_image_%2872dpi_Max_1254x836pix%29_4.jpg","datePublished":"2023-04-27T06:03:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-expands-contrast-media-portfolio-with-launch-of-mri-agent-pixxoscan-gadobutrol\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-expands-contrast-media-portfolio-with-launch-of-mri-agent-pixxoscan-gadobutrol\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-expands-contrast-media-portfolio-with-launch-of-mri-agent-pixxoscan-gadobutrol\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230426005641\/en\/1775265\/4\/2023_Pixxoscan_pressrelease_-_image_%2872dpi_Max_1254x836pix%29_4.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230426005641\/en\/1775265\/4\/2023_Pixxoscan_pressrelease_-_image_%2872dpi_Max_1254x836pix%29_4.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-expands-contrast-media-portfolio-with-launch-of-mri-agent-pixxoscan-gadobutrol\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"GE HealthCare Expands Contrast Media Portfolio with Launch of MRI Agent Pixxoscan (gadobutrol)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/751840","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=751840"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/751840\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=751840"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=751840"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=751840"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}